Therapeutic potential of stem cell-derived extracellular vesicles in osteoarthritis: preclinical study findings

Ki Hoon Kim¹, Jeong Hyun Jo¹, Hye Jin Cho², Tae Sub Park¹² and Tae Min Kim¹²*

Abstract
Extracellular vesicles (EVs) are nano-sized particles secreted by almost all cell types, and they mediate various biological processes via cell-to-cell communication. Compared with parental cells for therapeutic purposes, stem cell-derived EVs have several advantages such as reduced risk of rejection, less oncogenic potential, ease of long-term storage, lower chance of thromboembolism, and readiness for immediate use. Recent studies have demonstrated that EVs from stem cells, mostly from mesenchymal stem cells (MSCs) from various tissues, have anti-inflammatory, anti-oxidative, anti-apoptotic, and proliferative role in injured organs including osteoarthritic lesions. Herein, we provide a review about the up-to-date studies in preclinical application of stem cell-derived EVs in osteoarthritis animal arthritis models.

Keywords: EVs (extracellular vesicles), MSCs (Mesenchymal stem cells), OA (osteoarthritis)

Introduction
Among joint diseases, osteoarthritis (OA) is one of the most severe types of arthritis that is caused by loss of joint cartilage and bone [1]. Mostly, the articular damage is due to loss of self-repair capability of injured cartilage caused by mechanical stress, e.g., sudden or unadjusted movements, mechanical injury, excess weight, loss of muscle strength supporting joint, and damage in peripheral nerves [2]. Also, it is still under debate whether exercise increases the risk of osteoarthritis in the knee [3].

Osteoarthritis: its pathophysiology
So far various soluble mediators have been reported to be involved in the progression of OA. Readers are referred to other reviews on the detailed role of the role of pro-inflammatory (IL-1β, TNF-α, IL-6, IL-17) (Fig. 1) and anti-inflammatory cytokines that are involved in OA pathogenesis (IL-4, IL-10, IL-13) [4, 5]. For example, an elevated level of IL-1β and TNF-α was found in OA synovial fluid, synovial membrane, and subchondral bone cartilage [6]. Mechanistically, these cytokines down-regulated the synthesis extracellular matrix (ECM) component by inhibiting anabolic activities of chondrocytes. Another study showed that IL-1β reduces the expression of the type II collagen, which is a major ECM component constituting the cartilaginous tissues in several animal species [7, 8]. Also, the expression of Aggreican, which is one of the major components of the cartilage, was found to be decreased by IL-1β treatment in chondrocytes and cartilage [9]. Indirectly, IL-1β and TNF-α stimulate chondrocyte to produce a proteolytic enzyme such as matrix metalloproteinases (MMPs), including MMP-1 (interstitial collagenase), MMP-3 (stromelysin 1), MMP-13 (collagenase 3) [10–12]. In addition, ADAMTS (a disintegrin-like and metalloproteinase with thrombospondin motifs) of is also one of the major players in cartilage degradation in OA. It was
reported that the expression of ADAMTS-4 can be induced by IL-1β and TNF-α, while the expression of ADAMTS-5 was not affected [13]. In contrast, subsequent study has shown that IL-1β induced its mRNA expression in rabbit nucleus [14]. Other than these proteases, miR30a was also shown to play an important role in controlling ADAMTS-5 expression that was caused by IL-1β [15]. Also, IL-1β and TNF-α induce the generation of inflammatory cytokines such as IL-6 [14] and IL-8 [16], monocyte chemoattractant protein 1 (MCP1) [17] and CC-chemokine ligand 5 (CCL5) [18], all of which are well-reported players in sustaining tissue inflammation. IL-6 exists at a low concentration level in normal chondrocyte. However, its concentration in sera and chondrocytes is increased in osteoarthritic condition, after which it causes the increases in IL-1β and TGF-β, which in turn promoted the production of IL-6 [19, 20]. Studies also demonstrated that IL-6 stimulates the expression of MMP-1 and MMP-13 in bovine and humans (cell type) [21, 22], and IL-6 reduced the expression of type II collagen (cell type) [23]. Other studies showed that the expression of IL-17 is upregulated by IL-1β, TNF-α and IL-6, after which IL-17 upregulated NO and MMPs production [24]. In addition, IL-17 led to a reduced expression of proteoglycan [25].

Current treatment method for OA
Depending on the disease status, clinical protocols can be classified into surgical method, using NSAIDs (Nonsteroidal anti-inflammatory drugs), via physical therapy, opioids, or intra-articular injection of hyaluronic acid (Fig. 2). Although NSAIDs have been commonly used for relieving inflammation due to their analgesic and anti-inflammatory effect, side effects such as the organ toxicity (e.g., liver and kidney) have been critical. In particular, using NSAIDs for a long-term or repeated time can lead to gastrointestinal tract hemorrhage [26–28]. Thus, other alternatives, i.e., cellular therapies using autologous or allogenic origins are now becoming recognized as save and effective option. Also, application of induced pluripotent stem cell (iPSC)-derived chondrocytes may be another choice depending on the regulation and safety guidelines [29]. Although several protocols are currently available for clinical purposes [30], cell-based therapy inherently possess the risk of immune rejection and tumor formation in vivo [31, 32]. Accordingly, application of extracellular vesicles, which can be obtained from desired cell types during culture, would be an ideal cell-free strategy that can solve the problems that can be raised upon implementing cell therapy [29, 33, 34].

Isolation methods of EVs
Currently, various protocols are being used to isolate EVs. Classically, ultracentrifugation is recognized as the most standardized method for isolating a large scale of EVs. Other methods include immunoaffinity isolation (magnetic bead isolation), tangential flow filtration, size exclusion chromatography, and polymer precipitation [35–38]. Ultracentrifugation can be modified or further
optimized, such as applying density gradient force during ultracentrifugation for harvesting EVs with an enhanced purity. To obtain EVs with higher purity in a large amount, tangential flow filtration method has been developed. This technique enables the removal of cell debris and unnecessary biomolecules by filtering the cell culture supernatant using sterile hollow fiber polyethersulfone membrane [39]. This system may be ideal for producing in an industrial (20–50 l) or laboratory scale (e.g.,300 ml) [37, 40]. Size exclusion (chromatography) method is based on physical barriers, for example filters or chromatographs. Ideally, this technique enables removing many contaminating elements such as albumin or lipoproteins. Depending on the size of EVs that are of interest, a range of different pore sizes (0.8 or 0.2 μm) may be used [41, 42]. Finally, polymeric precipitation method is relatively easy and quick, and optimal for enriching EVs for small-scale experimental purposes. Precipitation mixtures are incubated with culture medium, and low speed centrifugation is used to concentrate EVs [43]. There is, however, a study showing the quality of RNA extracted from polymeric precipitation may not be optimal [44].

Characterization of EVs
EVs are collective term for heterogeneous nano-sized lipid-bilayerd membrane vesicles having 30-2000 nm diameter. Importantly, EVs play essential role in intercellular communications due to a large variety of biologically active signaling molecules within EVs, including RNA species (messenger RNA and small RNA), proteins, enzymes, lipids and DNA fragments [45]. So far various characterization methods are available. TEM (Transmission electron microscopy) and SEM (Scanning electron microscopy) are usually used for verifying their cup- or round- shape [46–49]. TEM is more commonly used than SEM [50, 51]. The diameter size as well as their size distribution can be measured by NTA (nanoparticle tracking analyzer) [49, 52]. Finally, the presence of EV-specific markers (CD9, CD63, CD81, TSG101, and Alix) [48, 49] can be examined by immunoblotting or flow cytometry.

Preclinical studies
EVs contain a wide spectrum of biomolecules including proteins, lipids, nucleic acids (DNAs, RNAs, small RNAs). Together with the notion that EVs are a natural player of cell-cell interaction in multicellular organisms, studies have focused on strengthening their specific function [53]. For example, miR-140-5p-overexpressing synovial MSC-derived exosomes led to an enhancement of chondrocyte proliferation and migration, and prevented OA in a medial meniscus OA rat model [54]. Other study showed that human embryonic MSC-derived exosomes injected in medial
| Cell types                                    | EV characterization methods | Main cargo                         | Animal models                                                                 | Results                                                                                                                                                                                                 | References |
|----------------------------------------------|----------------------------|------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Human embryonic stem cells                   | WB (CD81, TSG101, ALIX)   | Not mentioned                      | Surgical defect on trochlear grooves of the distal femurs osteochondral model in rats (1.5 mm diameter, 1 mm depth)                                      | Hyaline cartilage formation characterized by uniform distribution of high amounts of glycosaminoglycan (GAG) and type II collagen, and low amount of type I collagen                                                                 | [57]      |
| Synovial mesenchymal stem cells (SMSCs)      | WB (CD9, CD63, CD81, ALIX)| miR-140-5p                         | OA induced by medial meniscus surgery in rats                                      | Prevention of early OA and prevented the severe damage to knee articular cartilage with increased type II collagen deposition                                                                                     | [54]      |
| H1 human ES cell line                        | WB (CD9, CD63)            | Not mentioned                      | OA induced by medial meniscus surgery in rats                                      | Milder OA pathology such as roughened articular surface fibrillations below the superficial layer and some loss of lamina, with increased collagen II and decreased ADAMTS5 expression.                                    | [55]      |
| iPSCs- and synovial membrane-derived MSCs     | WB (CD9, CD63, TSG101)    | CD9, CD63 and TSG101               | Collagen-induced OA model in mice                                               | Re-formation of hyaline features with a smooth cartilage surface, regular cellular organization, and normal proteoglycan content. Decreased collagen I in animals treated with IMSC-Exos or SMMSC-Exos                                                    | [56]      |
| E1-MYC 16.3 human ESC-derived mesenchymal stem cells | WB (CD81, TSG101, ALIX) | Not mentioned                      | Surgical defect created on the trochlear grooves of the distal femurs osteochondral model in rats (1.5 mm diameter, 1 mm depth)                                      | Tissue regeneration deposition of s-GAG and type II collagen. Improved surface regularity and integration with the host cartilage                                                                 | [34]      |
| Murine Bone marrow mesenchymal stem cells    | FC (CD9, CD29, CD44, CD81, SCA-1), NTA | Not mentioned                      | Collagenase induced OA model in mice                                           | Protection against osteoarthritic damages via anti-apoptotic role                                                                                                                                                           | [58]      |
| Bone marrow mesenchymal stem cells           | FC (CD63, CD44, CD73)     | Not mentioned                      | Surgical defect created on rounded trephine grooves osteochondral model in dogs (3 mm diameter, 1 mm depth)                                      | Marked regeneration of cartilage tissues                                                                                                                                                                           | [59]      |
| Human Bone marrow mesenchymal stem cells     | NTA TEM (Transmission electron microscope) | miR-92a-3p                         | Collagenase induced OA model in mice                                           | The proliferation of chondrocytes                                                                                                                                                                                                 | [60]      |
| Mice Bone marrow mesenchymal stem cells      | NTA, TEM, FC (CD9, CD29, CD44, CD81, SCA-1) | Not mentioned                      | Collagenase induced OA model in mice                                           | Increased the matrix gene expression in MSCs and PHCs. miR-92-3p-mediated inhibition of WNT5A was shown.                                                                                                                                 | [61]      |
| Human Infrapatellar fat mesenchymal stem cells | NTA, TEM, WB (CD9, CD63, CD81) | miR-100-5p                          | Cutting the medial meniscus OA model in mice                                    | Induced a fewer plasmablasts and more Breg-like cells in lymph nodes.                                                                                                                                               | [62]      |
| Human Amniotic fluid stem cells              | WB (CD9, CD63, CD81, Rab5, HGF, TGF-β, IDO) | Not mentioned                      | MIA induced OA in rats                                                          | Induced an anti-inflammatory role on T and B cells                                                                                                                                                                  | [63]      |

Abbreviations: ADAMTS: a disintegrin-like and metalloproteinase with thrombospondin motifs; ESCs: embryonic stem cells; FC: flow cytometry; HGF: hepatocyte growth factor; IDO: indoleamine-pyrole 2,3-dioxygenase; iPSCs: induced pluripotent stem cells; MIA: moniodoacetate; MSCs: mesenchymal stem cells; mTOR: mammalian target of rapamycin; NTA: nanoparticle tracking analyzer; PHCs: primary human chondrocyte; S-GAG: sulfate-glycosaminoglycan; TEM: transmission electron microscopy; TGF: transforming growth factor; TSG101: tumor susceptibility gene 101; WB: western blot
meniscus OA mouse model improved the synthesis of cartilage regeneration [55]. Another study compared the therapeutic efficacy between EVs from iPSC derived -mesenchymal stem-like cells and synovial membrane-derived MSC in Collagenase-induced mouse OA model, and showed that EVs from iPSC derived MSC was better in reducing OA progression [56]. Similarly, in a rat model of osteochondral defect, EVs derived from human embryonic mesenchymal stems was able to reduce the disease progression [57]. Several mechanistic studies also showed that EVs from MSCs mediate cartilage repair by enhancing proliferation, attenuating apoptosis, modulating immune reactivity. For example, treatment of MSC-derived exosomes led to an enhanced activity of AKT and ERK cing proliferation, attenuating apoptosis, modulating immunology. In addition, EVs from mouse BM-MSCs osteochondral tissue in Surgical defect created on the phages over CD86+ M1 macrophages was found in the osteochondral tissue in Surgical defect created on the model [34]. In addition, EVs from mouse BM-MSCs showed a therapeutic effect in collagenase induced arthritis model, as shown by Protection from osteoarthritis damage and a reduction of apoptotic cells injected in mouse chondrocyte, with a significant improvement cartilage generation. Finally, EV treatment was able to reduce osteophyte formation in a mice model of OA [58]. In an OA model created by making a rounded trephine grooves osteochondral model in dogs (3 mm diameter, 1 mm depth), administration of mouse bone marrow MSC-derived EV led to a marked regeneration of cartilage and restoration of chondral tissue [59]. Also, it was shown that WNT5A expression was inhibited by miR-92a-3p delivery by exosomes, which led to an inhibition of cartilage degradation [60]. In a collagenase induced arthritis model in mice, EVs from mouse BM-MSCs inhibited T lymphocyte proliferation in a dose-dependent manner, and also decreased the percentages of CD4 and CD8 subsets. Also, fewer plasmablasts and more Breg-like cell in lymph nodes was found [61].

miRNAs are one of the major biological cargos in EVs from parental cells, and it was shown that miR-100-5p was enriched in the exosomes derived from human Infrapatellar fat mesenchymal stem cells. Upon being injected intra-articular into OA mice induced by destabilization of the medial meniscus, the OA progression was dramatically attenuated, as shown by the reduction of articular damage and amelioration of gait abnormality. Molecular study also demonstrated that miR-100-5p inhibited mTOR/ autophagy pathway [62]. Another study demonstrated that exosomes from miR-92a-3p-overexpressing BM-MSCs was able to promote the chondrocyte proliferation, and upregulated several matrix genes (Aggrecan, Col2A1, Sox9) and decreased a subset of other matrix genes (Col2A10, Runx2, MMP13, Wnt5A).

Another study showed that EVs from human amniotic fluid stem cells has therapeutic effect in MIA (Monoiodoacetate)-induced OA model in rats, as demonstrated by an enhanced pain tolerance and improved histological score. After 3 weeks of EV treatment, rat cartilage restoration with good surface regularity and with the characteristic of hyaline cartilage was shown. Moreover, markers of resolving macrophages (CD163, arginase 1, and TGFβ) were significantly increased after EV treatment [63]. Collectively, EVs from various stem cells alleviated the disease progression, as supported by results of tissue histology as well as inflammatory cytokine profiles in various preclinical OA models. We have provided a detailed list of studies that have attempted to use EVs from various parental cell types in OA animal models (Table 1).

**Conclusion**
EV carry out many different functions in organisms that include repair of tissue injuries, regulation of immune response, and inhibition of inflammation. The improvement in arthritic pathologies by MSCs is mostly due to cell-to-cell direct interaction and also by secretion of various soluble mediators. This review has presented MSC derived EVs as a cell-free treatment of joint damage and OA. It is currently accepted that the biological contents of EVs may significantly differ from those from parental cells, thus more extensive characterization of the membrane bound or luminal cargoes needed to further application of these unique nano-sized particles for therapeutic uses.

### Abbreviations
ACI: Autologous chondrocyte implantation; ADAMTS: A disintegrin-like and metalloproteinase with thrombospondin motifs; BM: Bone marrow; CCL5: CC-chemokine ligand 5; CD: Cluster of differentiation; Col2A1: Collagen type II alpha 1; ECM: Extracellular matrix; ESCs: Embryonic stem cells; EVs: Extracellular vesicles; FC: Flow cytometry; HGF: Hepatocyte growth factor; IDO: Indoleamine-pyrrole 2,3-dioxygenase; IL: Interleukin; iPSCs: Induced pluripotent stem cells; MCP1: Monocyte chemoattractant protein 1; MIA: Monoiodoacetate; MMP: Matrix metalloproteinase; MSCs: Mesenchymal stem cells; mTOR: Mammalian target of rapamycin; NO: Nitric oxide; NSAIDs: Non-steroidal anti-inflammatory drugs; NTA: Nanoparticle tracking analyzer; OA: Osteoarthritis; PHC: Primary human chondrocyte; Runx2: Runt-related transcription factor 2; SEM: Scanning electron microscopy; S-GAG: Sulfate-glycosaminoglycan; TEM: Transmission electron microscopy; TGF: Transforming growth factor; TNF: Tumor necrosis factor; TSG101: Tumor susceptibility gene 101; WB: Western blot

### Acknowledgments
This work was supported by Research Resettlement Fund for the new faculty of Seoul National University.

### Authors’ contributions
KHK, JHL, HJC, TSP and TMK wrote this review. TMK provided the general concepts and organized this manuscript. The author(s) read and approved the final manuscript.
Funding
This work was also supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1A02085481) (T.M.K).

Availability of data and materials
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 14 January 2020 Accepted: 23 March 2020
Published online: 15 April 2020

References
1. Goldring MB, Ostorro M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471–8.
2. Kenneth D, Brandt MD, Paul Dieppe MD, Radin MD EL. Etiopathogenesis of osteoarthritis. Rheum Dis Clin N Am. 2008;34(3):531–59.
3. Bosonworth NJ. Exercise and knee osteoarthritis: benefit or hazard? Can Fam Physician. 2009;55(9):871–8.
4. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokine in osteoarthritis pathobiology. Physiol Rev. 2002;92(1):237–46.
5. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33–42.
6. Hollander JL. Arthritis and allied conditions. Textbook Rheumatol J Med Educ. 1960;35(10):988.
7. Chadjichristos C, Gharor C, Kypriotou M, Martin G, Renard E, Ala-Kokko L, Suske G, de Combrugge B, Pujol JP, Galéra P. Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes. J Biol Chem. 2003;278(41):39762–72.
8. Shikabai M, Schube-Tarol G, John T, Mobasher A. Curcumin protects human chondrocytes from IL-1beta-induced inhibition of collagen type II and beta-1 integrin expression and activation of caspase-3 in an immunomorphological study. Ann Anat. 2005;187(5–6):487–97.
9. Nienfelt JJ, Willbrink B, Den Otter W, Huber J, Huber-Bruning O. The effect of human interleukin 1 on proteoglycan metabolism in human and porcine cartilage explants. J Rheumatol. 1990;17(6):818–26.
10. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Regulation of IL-8 expression by human articular chondrocytes. J Immunol. 1992;149(5):266–73.
11. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta. 1990;1052(3):366–78.
12. Reboul P, Pelletier JP, Tarcl D, Clouster JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest. 1996;97(5):1019–9.
13. Tortorella MD, Malfait AM, Decico C, Amer E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TSS (aggrecanase-2) in a model of cartilage degradation. Osteoarthr Cartil. 2001;9(6):539–52.
14. Seki S, Asanuma-Abe Y, Masuda K, Kawaguchi Y, Asanuma K, Muhleman C, Iwai A, Kimura T. Effect of small interference RNA (siRNA) for ADAMTS 5 on degradation of the rabbit anular needle-puncture model. Arthritis Res Ther. 2009;11(6):R166.
15. Ji Q, Xu X, Zhang Q, Kang L, Xu Y, Zhang K, Li L, Liang Y, Hong T, Ye Q. Wang Y. The IL-1β/AP-1/miR-30a/ADAMTS-5 axis regulates cartilage matrix degradation in human osteoarthritis. J Mol Med (Berl). 2016 Jul;94(7):771–84.
16. Lotz M, Terkeltaub R, Villiger PM. Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. J Immunol. 1992;148(2):466–73.
17. Villiger PM, Terkeltaub R, Lotz M. Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. J Clin Invest. 1992;90(2):488–96.
39. Busatto S, Vilanilam G, Ticer T, Lin WL, Dickson DW, Shapiro S, Bergese P, Wolfram J. Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells. 2018;7(12). https://doi.org/10.3390/cells7120273.

40. Vishnubhatla I, Corteling R, Stevanato L, Hicks C, Sinden J. The development of stem cell-derived exosomes as a cell-free regenerative medicine. J Cell Biol. 2014;3(2). https://doi.org/10.1002/jcb.25729.

41. György B, Módos K, Pällinger E, Palóczi K, Pásztor M, Misják P, Deli MA, Sipos A, Szalai A, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood. 2011;117(4):e39–48.

42. Théry C, Arriaga S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;3(1). https://doi.org/10.1002/0471143030.cb0322s30.

43. Alvarez ML, Khosroheidari M, Kanchi Ravi R, DiStefano JK. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012;82(1):924–32.

44. Taylor DD, Zacharias W, Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol Biol. 2011;7:235–46.

45. Lamichhane TN, Sokic S, Schardt JS, Raiker RS, Lin JW, Jay SM. Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. Tissue Eng Part B Rev. 2014;21(1):45–54.

46. Chernyshev VS, Ruschamadugu R, Tseng YH, Belnap DM, Jia Y, Branch KJ, Butterfield AE, et al. Size and shape characterization of hydrated and desiccated exosomes. Anal Bioanal Chem. 2015;407(12):3285–301.

47. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, Kittel A, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68(16):2667–88.

48. Li Z, Wang Y, Xiao K, Xiang S, Li Z, Weng X. Emerging role of exosomes in the joint diseases. Cell Physiol Biochem. 2018;47(5):2008–17.

49. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8(7). https://doi.org/10.3390/cells8070727.

50. Sokolova V, Ludwig AK, Homung S, Rotan O, Hom PA, Epplle M, Giebel B. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces. 2011;87(1):146–50.

51. Sharma S, Rasool H, Palanisamy V, Mathiesen C, Schmidt M, Wong DT, Gmizewski J. Structural-mechanical characterization of nanoparticle exosomes in human saliva, using correlative AFM, FESEM, and force spectroscopy. ACS Nano. 2010;4(4):1921–6.

52. Rupert DLM, Claudio V, Lässer C, Bally M. Methods for the physical characterization and quantification of extracellular vesicles in biological samples. Biochim Biophys Acta Gen Subj. 2017;1861(1 Pt A):3164–3171.

53. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and cell-derived vesicles. J Cell Biol. 2013;206(4):373–83.

54. Tso SC, Yuan T, Zhang YL, Yin WJ, Guo SC, Zhang CQ. Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. Tissue Eng Part A. 2017;23(11–12):180–95.

55. Wang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B, Zhou J, Heng BC, Zou XH, Ouyang H, Liu H. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res Ther. 2017;8(1):189.

56. Zhu Y, Wang Y, Zhao B, Niu X, Hu B, Li Q, Zhang J, Ding J, Chen Y, Wang Y. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res Ther. 2017;8(1):64.

57. Zhang S, Chu WC, Lai RC, Lim SK, Hui JH, Toh WS. Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration. Osteoarthr Cartil. 2016;24(12):2135–40.

58. Cosenza S, Toupet K, Jorgensen C, Noel D. Mesenchymal stem cell-derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci Rep. 2017;7(1).

59. Cosenza S, Toupet K, Jorgensen C, Noel D. Mesenchymal stem cell-derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci Rep. 2017;7(1).

60. Mao G, Zhang Z, Hu S, Zhang Z, Chang Z, Huang Z, Liao W, Kang Y. Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A. Stem Cell Res Ther. 2018;9(1). https://doi.org/10.1186/s13287-018-1004-0.

61. Cosenza S, Toupet K, Maumus M, Luz-Crawford P, Blanc-Brude O, Jorgensen C, Noel D. Mesenchymal stem cell-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. 2018;8(5):1399–410.

62. Wu J, Jiang L, Chen C, Yang J, Zeng WN, Li T, Chen H, Huang S, Fu Z, Li J, et al. miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. Biomaterials. 2019;206:87–100.

63. Zavatti M, Beretti F, Cassio F, Bertucci E, Maier M. Comparison of the therapeutic effect of amniotic fluid stem cells and their exosomes on monooiodoacetate-induced animal model of osteoarthritis. Biofactors. 2019:1–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.